Most Recent
Construction PRO
AkzoNobel is back in court after trial concluded in proceedings over the protective coating used on the Ichthys LNG project, claiming Japanese oil company Inpex's bid to have a double discount issues determined by the court could increase any damages owed by $1 billion.
Construction PRO
Infrastructure fund manager Dexus must pay a total of $30 million in legal costs to Australia Pacific Airports Corporation and fellow APAC shareholders, after losing its case over a default notice that has forced a sale of Dexus' stake in the airport operator.
Construction PRO
The company that paid $60 million for bankrupt Jon Adgemis' Noah's Backpackers hotel in Bondi Beach has been ordered to cough up $6 million in GST refunds to a Singapore special purpose vehicle that arranged a loan for the purchase.
Construction PRO
Hearing a fight over $40 million in costs in a case over the sale of Dexus shares in Australia Pacific Airport Corporation, a judge has said he doubts the airport operator can recover the hundreds of thousands of dollars spent on a media consultant during the dispute.
Construction PRO
Fortescue and its joint venture partners on the Iron Bridge iron ore project in Western Australia have sued two companies that allegedly supplied defective pipeline for the project.
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
Hugo Boss AG has successfully opposed an application to trade mark 'Mafiaboss' for clothing, footwear and leather goods, with a delegate finding the addition of 'mafia' was not enough to distinguish the trade marks.
A judge has largely refused a bid by DGR Global to amend its “tortured” case against Baker McKenzie and others for a fourth time, calling the changes "renovations rather than mere repair".
A trade mark dispute between US singer Katy Perry and an Australian fashion designer is back in court for a fight on damages and injunctions, after the designer secured a win before the High Court in March.
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.